Item 7.01 Regulation FD Disclosure.
The Company confirms that it remains in active negotiations with the
The Company does not expect to provide updates related to negotiation of the procurement agreement prior to execution with BARDA.
The information in this Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Forward-Looking Statements
The Company cautions you that statements included in this report that are not a
description of historical facts are forward-looking statements. These
forward-looking statements include statements regarding negotiation and
execution of the sole-source contract with BARDA, the timing and amount of the
initial procurement and shipment of TEMBEXA under the contract, and additional
procurements and shipments under the contract. The inclusion of forward-looking
statements should not be regarded as a representation by the Company that any of
these results will be achieved. Actual results may differ from those set forth
in this report due to the risks and uncertainties associated with government
procurement negotiations, continued funding for BARDA and smallpox antiviral
development and procurement, and geopolitical and market conditions, as well as
risks and uncertainties inherent in the Company's business, including those
described in the Company's other filings with the
© Edgar Online, source